Skip to content
Photographer: Galit Rodan/Bloomberg

Cannabis Allure Proves Irresistible for Tobacco Company Altria

Updated on

Cannabis Allure Proves Irresistible for Tobacco Company Altria

  • Bet on marijuana is a bid to offset tobacco’s steady decline
  • Altria has the option to take majority control going forward
Inside The CannTrust Holdings Cannabis Production Facility Ahead Of Marijuana Legalization
Photographer: Galit Rodan/Bloomberg

Altria Group Inc., the U.S. maker of Marlboros, made a $1.8 billion investment in a Canadian pot company Friday based on a simple premise: Cannabis is growing fast, and cigarettes are not.

Altria has agreed to take a 45 percent stake in Toronto-based marijuana producer Cronos Group Inc., marking a major tobacco company’s first foray into cannabis. It has the option to take majority control in the future. The tobacco giant simultaneously said it will kill two of its next-generation products, fueling talk that a potential deal with Juul Labs Inc. could come soon.

From Earlier: Altria Is Said to Discuss Large Minority Stake in Juul

With U.S. smoking rates falling fast, Richmond, Virginia-based Altria is under pressure to find new avenues to expand. Marijuana is now allowed in an increasing number of states but is still illegal on the federal level in the U.S. That makes Canada, which legalized recreational use in October, a large laboratory for the nascent industry.

Support Builds

A majority of Americans favor marijuana legalization as opposition wanes

Source: Pew Research Center

“We believe cannabis is an excellent strategic fit for tobacco,” Jefferies analyst Owen Bennett said in a research note earlier this week. It’s a logical fit, because “big tobacco knows how to cultivate crop, knows how to deal with regulators, they are at the forefront of vaporization technology, and they also arguably have less reputational risk than other fast-moving consumer goods," he said.

Related: Pot Sector Regains Its Mojo After Altria’s $1.8 Billion Deal

It’s clear Altria has reassessed its competitive position. It also announced Friday that it will discontinue two of its next-generation tobacco products and its oral nicotine-containing ones to focus on “more compelling reduced-risk tobacco product opportunities.” The company attributed this to regulatory restrictions and lack of financial prospects for those products.

This suggests “an announcement to acquire a stake in Juul could come very soon,” Wells Fargo analyst Bonnie Herzog said in a Friday research note. Juul could compliment the cannabis business, she said.

Altria spokesman Steven Callahan declined to comment beyond the company’s press release.

Altria shares rose as much as 3.2 percent to $56.14 on Friday. Its stock had fallen 24 percent this year through Thursday’s close -- illustrating how investors had become pessimistic about the company’s future amid rising regulations and taxes on tobacco.

Next Moves

The company isn’t likely to rush into exercising the warrants that could bump its stake up to 55 percent, but it’s possible that Cronos will eventually become part of the tobacco giant, said Bloomberg Intelligence analyst Kenneth Shea.

“It looks like an understanding that they would become one and the same,” Shea said, noting that Altria will also have four of seven board seats.

Altria got a good deal, particularly as Cronos is one of a dwindling number of licensed cannabis producers that haven’t already established an exclusive relationship with a consumer products company, he said.

Cronos shares, meanwhile, surged as much as 33 percent to $13.95 in New York. Altria’s offer of C$16.25 a share represents a 16 percent premium from Thursday’s closing price. Peers in the marijuana sector also gained, with Aurora Cannabis Inc. rising as much as 11 percent, Aphria Inc. adding 19 percent, Canopy Growth Corp. rising 7.3 percent and Tilray Inc. gaining 4.8 percent.

Cowen analyst Vivien Azer said it’s not surprising that Altria opted for a pathway to a majority control of Cronos. Altria is paying 25 times forward sales, she said, and in her view, Altria is “buying their way out of a bind” after almost two decades of volume decline for U.S. cigarettes, and a challenging 2018 for e-cigarettes.

Falling Appeal

U.S. smoking rates have steadily declined over the last decade

Source: CDC

* 2018 data is January through March

Regulatory Expertise

Cronos CEO Mike Gorenstein said the partnership with Altria doesn’t limit the cannabis firm from engaging with other strategic partners.

Read more: A crash course for investors on lingo of (legal) weed

“In fact, we think this partnership makes us collectively a more attractive partner” for other potential investors, Gorenstein said on a conference call Friday. The most attractive piece of the partnership is Altria’s experience dealing with regulatory agencies, he said.

Altria has been grappling with a Food and Drug Administration that’s intent on strengthening restrictions on some of the vaping products that have caught on with younger users.

IQOS, Intellectual Property

Philip Morris International Inc., declined to comment on the deal, but said it doesn’t change anything with respect to its plan to use products like its smoke-free IQOS device to replace cigarettes.

Philip Morris, which was spun off from Altria and sells the Marlboro brand internationally, has been trying to get approval for Altria to market IQOS in the U.S. Separately, it has asked for regulatory permission to say the device carries a lower health risk than regular tobacco products.

Related: As Altria Eyes Pot, Philip Morris CEO Ignores Peer Pressure

Cronos’s Gorenstein said his company and Altria agree that developing brands and intellectual property is more valuable than growing plants and should be the focus going forward.

“When we were strategically planning how we would enter cannabis years ago, one of the companies that we looked at and had a lot of respect and admiration for was Altria,” he said. “It’s worth noting that Altria does not grow their own tobacco. We think that model of growing your own plants is very difficult to scale and to execute well. That was something we’re very aligned with.”

(Adds analyst comment starting in sixth paragraph.)